+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neurotransmitter"

Cholinergic Drugs Market Report 2025 - Product Thumbnail Image

Cholinergic Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Anticholinergic Drugs Market Report 2025 - Product Thumbnail Image

Anticholinergic Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
From
From
From
Muscarinic Acetylcholine Receptor Market Report 2025 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Myotonic Dystrophy - Pipeline Insight, 2025 - Product Thumbnail Image

Myotonic Dystrophy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Glutamate Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Glutamate Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
5-HT2 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2 Agonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Dopamine D2 Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Dopamine D2 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
GABA A Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABA A Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Drug-Resistant Refractory Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Drug-Resistant Refractory Epilepsy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
5-HT1D Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT1D Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Parkinson's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Parkinson's Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
Migraine - Pipeline Insight, 2025 - Product Thumbnail Image

Migraine - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Epilepsy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Autistic Disorder- Pipeline Insight, 2025 - Product Thumbnail Image

Autistic Disorder- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Dopamine D1 Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Dopamine D1 Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Neurotransmitter market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neurotransmitters are chemicals that are released by neurons to send signals to other cells. These drugs are used to treat a variety of neurological disorders, including depression, anxiety, and schizophrenia. Neurotransmitter drugs work by either increasing or decreasing the amount of neurotransmitters in the brain. The Neurotransmitter market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Eli Lilly, and Merck. Other companies such as Novartis, AstraZeneca, and Johnson & Johnson also have a presence in the Neurotransmitter market. Show Less Read more